Logo

The US FDA Approves Takeda’s Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis (EoE)

Share this
Takeda

The US FDA Approves Takeda’s Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis (EoE)

Shots:

  • The approval was based on the results from 2 trials (Study 1) & (Study 2) evaluating the safety & efficacy of Eohilia (2mg, BID) vs PBO in patients (aged 11-56yrs. & 11-42yrs.) with EoE. The efficacy endpoints of the trials were histologic remission & change from baseline in patient-reported DSQ post 12wks of treatment
  • The results depicted that 53.1% vs 1% & 38% vs 2.4% of patients achieved histologic remission whereas the absolute change from baseline in DSQ combined score were -10.2 vs -6.5 & -14.5 vs -5.9. It was also seen that Eohilia was not safe & effective as EoE treatment for longer than 12wks.
  • Eohilia (corticosteroid) expected to be made available in 2mg/10mL dosage by the end of Feb 2024

Ref: Takeda | Image: Takeda

Related News:- Takeda Reports the Results for TAK-861 in P-IIb Trials and Expects to Advance into P-III Trial for the Treatment Narcolepsy Type 1

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions